WO2005105118A1 - Procede de traitement d'hypocalcemie, d'osteoporose et de fractures - Google Patents

Procede de traitement d'hypocalcemie, d'osteoporose et de fractures Download PDF

Info

Publication number
WO2005105118A1
WO2005105118A1 PCT/RU2005/000202 RU2005000202W WO2005105118A1 WO 2005105118 A1 WO2005105118 A1 WO 2005105118A1 RU 2005000202 W RU2005000202 W RU 2005000202W WO 2005105118 A1 WO2005105118 A1 WO 2005105118A1
Authority
WO
WIPO (PCT)
Prior art keywords
fractures
treatment
osteoporosis
κaltsiya
πeρelοmοv
Prior art date
Application number
PCT/RU2005/000202
Other languages
English (en)
Russian (ru)
Inventor
Grigory Nikolaevich Konygin
Nikolaj Sergeevich Strelkov
Evgeny Pavlovich TYULKIN
Viktor Vladimirovich Pozdeev
Petr Nikolaevich Maksimov
Aleksandr Nikolaveich Filippov
Sergej Borisovich Shishkin
Faat Zalalutdinovich Gilmutdinov
Gennady Alekseevich Dorofeev
Evgeny Petrovich Yelsukov
Original Assignee
TYULKIN Artem Evgenevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TYULKIN Artem Evgenevich filed Critical TYULKIN Artem Evgenevich
Publication of WO2005105118A1 publication Critical patent/WO2005105118A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • the method of treating hyperscalcemia is known, including the intramuscular administration of 5% - 10% medicinal preparations of calcium, calcium, calcium, calcium, and other substances. 91).
  • the disadvantage of this method is the invasive method of administering drugs, quickly eliminating them from the circuit, and, as a result, is not sufficient.
  • the objective of this invention is to create a method that will quickly improve the effectiveness of an effective treatment of SALVISING FOX (SAFETY 26) 2 gi ⁇ altsiemy, ⁇ s ⁇ e ⁇ za ⁇ azlichn ⁇ g ⁇ genesis ⁇ s ⁇ e ⁇ mieli ⁇ a, ⁇ s ⁇ ny ⁇ ⁇ is ⁇ , ⁇ s ⁇ e ⁇ nd ⁇ z ⁇ v, ⁇ s ⁇ e ⁇ nd ⁇ a ⁇ y, ⁇ a ⁇ l ⁇ giches ⁇ i ⁇ ⁇ e ⁇ el ⁇ m ⁇ v ⁇ nechn ⁇ s ⁇ ey, and ⁇ e ⁇ el ⁇ m ⁇ v ⁇ . ⁇ ., not ⁇ dve ⁇ gaya ⁇ atsien ⁇ v ⁇ e ⁇ a ⁇ ivn ⁇ mu vmesha ⁇ els ⁇ vu, us ⁇ anya ⁇ de ⁇ e ⁇ y ⁇ s ⁇ ny ⁇ ⁇ aney without i ⁇ ⁇ ezi ⁇ vaniya or replacement.
  • P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ s ⁇ glasn ⁇ s ⁇ s ⁇ ba treatment gi ⁇ altsiemy, ⁇ s ⁇ e ⁇ za, ⁇ e ⁇ el ⁇ m ⁇ v, v ⁇ lyuchayuscheg ⁇ ⁇ imenenie ⁇ e ⁇ a ⁇ a ⁇ v ⁇ altsiya, ⁇ itsinalnye ⁇ ve ⁇ dye dis ⁇ e ⁇ snye ⁇ is ⁇ alliches ⁇ ie or ⁇ able ⁇ i ⁇ vannye ⁇ is ⁇ alliches ⁇ ie le ⁇ a ⁇ s ⁇ vennye ⁇ e ⁇ a ⁇ a ⁇ y ⁇ altsiya ⁇ edva ⁇ i ⁇ eln ⁇ izmelchayu ⁇ d ⁇ am ⁇ n ⁇ g ⁇ s ⁇ s ⁇ yaniya, ⁇ imenyayu ⁇ ⁇ e ⁇ aln ⁇ 2-4 ⁇ aza daily d ⁇ zami ⁇ 0 5-
  • SIGNIFICANT FOX (DR. 26) 3 shredders handle the shredding of well-known, solid, dispersed crystalline or processed crystalline products.
  • the processing unit is supplied with an energy load of 0.4 - 50.0 kJ / g. In this way, they receive a mechanically treated calcium sample in an amorphous state with particle sizes not exceeding 1 mm.
  • the large size and the nanometer size of particles in the range of 50-300 nm ensure a high bioavailability of the drug.
  • Diagnosis systemic juvenile disease, hypecalcemia, pain syndrome.
  • crushed calcium glucose was used in an amorphous state with a particle size of 50-300 nm.
  • a 6-month treatment course with the adjoined treatment is provided.
  • the content of Ca in the blood serum was normalized, the pain syndrome disappeared.
  • Example 2. Patient B. 12 years.
  • Diagnosis distal metastasis system, pain, pain syndrome.
  • crushed calcium glucose was used in an amorphous state with a particle size of 50-300 nm.
  • the 8-month treatment course with the adjoined treatment is given.
  • the defect of the external tissue was filled with a constricted bone, the pain syndrome disappeared. With this great patient, they will remove the need for harsh surgical intervention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention relève de la médecine et concerne notamment un traitement conservateur hautement efficace d'hypocalcémie, d'ostéoporose d'origines différentes, d'ostéomyélite, de kystes osseux, d'ostéochondroses, d'ostéochondropathies, de fractures et de fractures pathologiques de membres inférieurs, etc. Selon la présente invention, des préparations médicamenteuses officinales solides de calcium, sous forme de dispersions cristallines ou de comprimés cristallins, sont préalablement broyées jusqu'à un état amorphe afin que la taille des particules ne dépasse pas 1 micromètre. Les préparations ainsi obtenues sont administrées péroralement 2 à 4 fois par jour, sous forme de doses de 0,5 à 1,0 grammes, suivant des cycles de traitement de 15 à 20 jours et des interruptions de 1 à 2 semaines, jusqu'au rétablissement complet.
PCT/RU2005/000202 2004-05-05 2005-04-18 Procede de traitement d'hypocalcemie, d'osteoporose et de fractures WO2005105118A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2004113712/14A RU2268053C1 (ru) 2004-05-05 2004-05-05 Способ лечения гипокальциемий, остеопорозов, переломов
RU2004113712 2004-05-05

Publications (1)

Publication Number Publication Date
WO2005105118A1 true WO2005105118A1 (fr) 2005-11-10

Family

ID=35241431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2005/000202 WO2005105118A1 (fr) 2004-05-05 2005-04-18 Procede de traitement d'hypocalcemie, d'osteoporose et de fractures

Country Status (2)

Country Link
RU (1) RU2268053C1 (fr)
WO (1) WO2005105118A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179982A2 (fr) * 2007-07-20 2010-04-28 Konygin, Grigory Nikolaevich Production de sels de calcium de l'acide gluconique amorphes et cristallo-amorphes activés mécaniquement

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2506071C1 (ru) * 2012-12-04 2014-02-10 Феликс Хусаинович Камилов Мазь с наносубстанцией кальция глюконата для лечения кожных заболеваний, связанных с недостатком кальция в организме

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94022264A (ru) * 1992-08-26 1996-05-27 Американ Дентл Ассошиэйшн Хелт Фаундейшн (US) Аморфные соединения кальция, способ их получения, способ обработки и реминерализации зубов, сжатый раствор, насыщенный углекислым газом, содержащий аморфное соединение кальция, неводная дисперсия карбонатной соли и кислоты или ее кислой соли, способ обработки зубной ткани неводной дисперсией
RU2147885C1 (ru) * 1999-02-09 2000-04-27 Чернов Юрий Николаевич Способ лечения остеопороза
US20030139354A1 (en) * 2000-06-02 2003-07-24 Herwig Buccholz Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94022264A (ru) * 1992-08-26 1996-05-27 Американ Дентл Ассошиэйшн Хелт Фаундейшн (US) Аморфные соединения кальция, способ их получения, способ обработки и реминерализации зубов, сжатый раствор, насыщенный углекислым газом, содержащий аморфное соединение кальция, неводная дисперсия карбонатной соли и кислоты или ее кислой соли, способ обработки зубной ткани неводной дисперсией
RU2147885C1 (ru) * 1999-02-09 2000-04-27 Чернов Юрий Николаевич Способ лечения остеопороза
US20030139354A1 (en) * 2000-06-02 2003-07-24 Herwig Buccholz Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOLDYREV V.V. ET AL: "Metody poluchenya I modifikatsii lekarstvennykh preparatov, osnovannye na dostizhennykh khimii tverdogo tela.", no. 2, 2000, pages 143 - 148 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179982A2 (fr) * 2007-07-20 2010-04-28 Konygin, Grigory Nikolaevich Production de sels de calcium de l'acide gluconique amorphes et cristallo-amorphes activés mécaniquement
EP2179982B1 (fr) * 2007-07-20 2018-03-07 Konygin, Grigory Nikolaevich Sel de calcium de l'acide gluconique amorphe activé mécaniquement

Also Published As

Publication number Publication date
RU2004113712A (ru) 2005-10-27
RU2268053C1 (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
TW200911277A (en) An agent for preventing or decreasing peripheral neuropathy by an anticancer drug
CN103142948B (zh) 一种预防和治疗呼吸道疾病药物及其制造方法
WO2005105118A1 (fr) Procede de traitement d'hypocalcemie, d'osteoporose et de fractures
CN103007162A (zh) 用于预防流感的中药香囊
CN100525817C (zh) 一种治疗结核病的药物组合物及其制备方法
CA2780771C (fr) Composition pharmaceutique a action antimicrobienne et cicatrisante pour application externe, et procede de fabrication
CN104587470B (zh) 一种促进骨质疏松性骨折术后骨愈合的药物组合物及其应用
US20060251738A1 (en) Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
JPH03503648A (ja) 磁気により作用する同種療法薬ならびにそれらの製造方法およびそれらの投与方法
US7871648B2 (en) Herbal formulation for the treatment of bone fractures and osseous defects
Eatelaf The percutaneous effect of black seed (Nigella sativa) oil as external topical treatment on bone healing in rabbits
CN103007155A (zh) 用于防治感冒的中药香囊
CN110464749A (zh) 治疗鼻炎的外用中药药油
Mohan et al. Naturopathy and endodontics–A synergistic approach
WO2014109678A1 (fr) Méthode et produit pour traiter les arthrites et les arthroses
Klinghardt et al. Lyme disease: a look beyond antibiotics
JP2001514671A (ja) 癌治療薬
CN103585460B (zh) 一种用于牙龈止血的填塞剂
RU2763171C1 (ru) Способ получения эмульсии, содержащей нано- и микрокапсулированные биологически активные вещества
RU2670680C1 (ru) Способ нейрорепарации при пояснично-крестцовом синдроме
ES2387057B1 (es) Uso de un extracto vegetal como principio activo para la elaboración de un producto con actividad farmacológica para el tratamiento de lesiones tisulares y procedimiento de obtención del extracto
RU2147880C1 (ru) Лекарственное средство для лечения пациентов с хроническим алкоголизмом и способ их лечения
KR20170015348A (ko) 골, 연골, 치아 및 치주의 재생 및 종양 및 낭포의 치료를 위한 제형
CN1049590C (zh) 全蝎擦剂
KR20210127647A (ko) 타닌을 탄소나노입자와 탄소입자에 흡수시켜 제조한 바이러스 감염예방 및 치료제 시스템

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase